Oncologists talk about the clinical application of ddPCR technology

At the annual meeting of the American Society for Cancer Research held in early April, many researchers demonstrated the clinical application of liquid biopsy based on droplet digital PCR (ddPCR)

Bio-Rad's ddPCR technology has been cited in more than 900 liquid biopsy literatures

Metastatic breast cancer

Dr.

The researchers measured mutations in two genes (PIK3CA and ESR1) related to drug resistance

They found that the presence of PIK3CA and ESR1 mutations in ctDNA was associated with the patient's response to abemaciclib, but there was no such association in tissue samples

"These results support the use of ctDNA and liquid biopsy to identify molecular changes that may help therapy choices," Dr.

Malignant pleural mesothelioma

Malignant pleural mesothelioma (MPM) is a relatively rare and aggressive cancer

The researchers compared the genetic differences between the tumors and normal tissues of 11 patients and developed a ddPCR analysis to detect disease-specific ctDNA

"Detecting ctDNA requires a highly sensitive method, and ddPCR technology is very suitable

HER2-negative breast cancer

Dr.

This phase III clinical trial was carried out in more than 80 cancer centers in France and has recruited 1,000 patients with HER2-negative metastatic breast cancer undergoing endocrine therapy

"Droplet digital PCR is a cost-effective solution that allows us to track ESR1 mutations in thousands of ctDNA samples in real time," said Dr.